EnhydrisPECorp
Long/short equity, research analyst, biotech, healthcare

Short Vanda's Pending Catalyst For A 30% Gain

The bulls are sharpening their horns in sweet anticipation of Vanda Pharmaceuticals' (NASDAQ:VNDA) upcoming Advisory Committee Meeting with the FDA for tasimelteon's New Drug Application (NDA). Tasimelteon is a circadian regulator in development as an indication for Non-24Hr disorder in the totally blind.

Last December, Vanda reported positive Phase III data for tasimelteon, causing the stock to surge 166% year-to-date. Adding fuel to the fire, the FDA recently agreed to bestow upon tasimelteon a highly coveted "Priority Review". The drug is thus set for an Advisory Committee hullabaloo on November 14th, with a target PDUFA date of January 31, 2014. With peak sales projected to top $500 M per year for a company with a sub $300...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details